Want to see IN:MARKSANS full AI Analyst Report?
MARKSANS Stock Chart & Stats
₹182.05
-₹6.40(-2.21%)
At close: 4:00 PM EST
₹182.05
-₹6.40(-2.21%)
Day’s Range― - ―
52-Week Range₹155.50 - ₹281.40
Previous CloseN/A
Volume681.00K
Average Volume (3M)99.03K
Market Cap
₹117.19B
Enterprise Value₹108.98B
Total Cash (Recent Filing)₹9.90B
Total Debt (Recent Filing)₹3.43B
Price to Earnings (P/E)28.0
Beta1.36
Next Earnings
Aug 07, 2026EPS Estimate
3.3Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)9.23
Shares Outstanding453,163,760
10 Day Avg. Volume119,310
30 Day Avg. Volume99,030
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.35
Price to Sales (P/S)2.41
P/FCF Ratio20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.33
Revenue Forecast (FY)₹34.39B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthMulti-year revenue growth demonstrates expanding market reach and product adoption across dosage forms and geographies. Durable top-line expansion supports scale benefits, spreads fixed costs, and underpins sustained cash generation and reinvestment capacity over the next several quarters to years.
Profitability (Net Margins)Mid‑teens net margins indicate persistent pricing power and operating efficiency across the product portfolio. Such sustained margins provide a cushion against input cost swings, enabling reinvestment in regulated‑market compliance and manufacturing, supporting durable earnings quality.
Conservative Balance SheetA conservatively financed balance sheet with very low leverage and a growing equity base gives the company flexibility to fund capex, regulatory investments or targeted M&A without stretching liquidity. This resilience reduces downside risk in cyclical stress periods.
Bears Say
Gross Margin CompressionSharp gross margin compression in FY2026 suggests sustained input-cost pressure, pricing erosion or adverse product mix. If structural, it reduces operating leverage and free cash flow, forcing either margin-restoring pricing, cost cuts or lower reinvestment—risking growth or competitiveness.
Volatile Cash ConversionHistorically uneven operating cash conversion and periods of very low free cash flow undermine funding predictability for capex, compliance spending and debt servicing. Continued volatility raises execution risk and can constrain strategic choices despite episodic FY2026 improvement.
Rising Debt Vs Earlier YearsAn uptick in borrowings, even from a low base, is a watch item given margin and cash‑flow variability. Continued debt increases would reduce financial flexibility and raise interest expense risk, particularly if margins remain under pressure or cash conversion weakens.
Marksans Pharma Limited News
MARKSANS FAQ
What was Marksans Pharma Limited’s price range in the past 12 months?
Marksans Pharma Limited lowest stock price was ₹155.50 and its highest was ₹281.40 in the past 12 months.
What is Marksans Pharma Limited’s market cap?
Marksans Pharma Limited’s market cap is ₹117.19B.
When is Marksans Pharma Limited’s upcoming earnings report date?
Marksans Pharma Limited’s upcoming earnings report date is Aug 07, 2026 which is in 6 days.
How were Marksans Pharma Limited’s earnings last quarter?
Marksans Pharma Limited released its earnings results on May 26, 2026. The company reported ₹3.25 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.25.
Is Marksans Pharma Limited overvalued?
According to Wall Street analysts Marksans Pharma Limited’s price is currently Overvalued.
Does Marksans Pharma Limited pay dividends?
Marksans Pharma Limited pays a Annually dividend of ₹0.9 which represents an annual dividend yield of 0.31%. See more information on Marksans Pharma Limited dividends here
What is Marksans Pharma Limited’s EPS estimate?
Marksans Pharma Limited’s EPS estimate is 3.3.
How many shares outstanding does Marksans Pharma Limited have?
Marksans Pharma Limited has 453,163,760 shares outstanding.
What happened to Marksans Pharma Limited’s price movement after its last earnings report?
Marksans Pharma Limited reported an EPS of ₹3.25 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.528%.
Which hedge fund is a major shareholder of Marksans Pharma Limited?
Currently, no hedge funds are holding shares in IN:MARKSANS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marksans Pharma Limited
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―
Sanofi India Limited
―